Reduced intensity conditioning regimens -: Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma

被引:127
作者
Hentschke, P
Barkholt, L
Uzunel, M
Mattsson, J
Wersäll, P
Pisa, P
Martola, J
Albiin, N
Wernerson, A
Söderberg, M
Remberger, M
Thörne, A
Ringdén, O
机构
[1] Huddinge Univ Hosp, Ctr Allogene Stem Cell Transplantat, SE-14186 Stockholm, Sweden
[2] Huddinge Univ Hosp, Div Immunol Microbiol & Pathol, SE-14186 Stockholm, Sweden
[3] Huddinge Univ Hosp, Dept Radiol, SE-14186 Stockholm, Sweden
[4] Huddinge Univ Hosp, Dept Surg, SE-14186 Stockholm, Sweden
[5] Karolinska Univ Hosp, Karolinska Inst, Dept Oncol, Stockholm, Sweden
关键词
reduced intensity conditioning; stem cell transplantation; solid tumor;
D O I
10.1038/sj.bmt.1703811
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
We have evaluated whether allogeneic hematopoietic stem cell transplantation (HSCT) could induce an antitumor effect in patients with metastatic solid tumors. A total of 12 HLA-identical siblings and 6 HLA-A-, -B- and -DRbeta1-compatible unrelated grafts were used. Diagnoses were adenocarcinoma of kidney (n = 10), colon (n = 6), breast (n = 1) and cholangiocarcinoma (n = 1). Conditioning was fludarabine 30 mg/m(2)/day for 3 days and 2 Gy of total body irradiation. Recipients of unrelated HSCT were also given thymoglobuline and two additional days of fludarabine. The median CD34 + cell dose was 7.5 x 10(6)/ kg. Immunosuppression was mycophenolate mofetil and cyclosporin. Among all, 12 patients became complete donor chimeras within a median of 28, 29 and 65 days for B, myeloid and T cells, respectively. Two patients rejected the grafts, one developed marrow aplasia and three were mixed chimeras. The probability of grades II-IV acute graft-versus-host-disease (GVHD) was 57%. Regression of all tumor metastases was seen in one patient with colon carcinoma. Another patient with colon and two with renal carcinoma had regression of lung metastases, but progression of metastases in the liver and/or bone. Necrosis of lung metastasis was found in one further patient with renal carcinoma who died of graft-versus-host-disease (GVHD). In all, 10 patients died; four of transplant-related complications, one of trauma and five of progressive disease. Thus, progression was common after allogeneic HSCT in unselected patients with advanced solid tumors. However, the regression of some metastases associated with GVHD provides suggestive evidence that the GVHD effect may occur in renal and colon adenocarcinoma using reduced intensity conditioning.
引用
收藏
页码:253 / 261
页数:9
相关论文
共 44 条
[1]  
APPELBAUM FR, 1995, SEMIN ONCOL, V22, P405
[2]  
Appelbaum FR, 1997, SEMIN ONCOL, V24, P114
[3]   Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia [J].
BenYosef, R ;
Or, R ;
Nagler, A ;
Slavin, S .
LANCET, 1996, 348 (9036) :1242-1243
[4]   Risk factors for chronic graft-versus-host disease after bone marrow transplantation:: a retrospective single centre analysis [J].
Carlens, S ;
Ringdén, O ;
Remberger, M ;
Lönnqvist, B ;
Hägglund, H ;
Klaesson, S ;
Mattsson, J ;
Svahn, BM ;
Winiarski, J ;
Ljungman, P ;
Aschan, J .
BONE MARROW TRANSPLANTATION, 1998, 22 (08) :755-761
[5]   Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia [J].
Carlens, S ;
Aschan, J ;
Remberger, M ;
Dilber, MS ;
Ringdén, O .
BONE MARROW TRANSPLANTATION, 1999, 24 (06) :629-635
[6]   The role of disease stage in the response to donor lymphocyte infusions as treatment for leukemic relapse [J].
Carlens, S ;
Remberger, M ;
Aschan, J ;
Ringdén, O .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (01) :31-38
[7]   Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses [J].
Childs, R ;
Clave, E ;
Contentin, N ;
Jayasekera, D ;
Hensel, N ;
Leitman, S ;
Read, EJ ;
Carter, C ;
Bahceci, E ;
Young, NS ;
Barrett, AJ .
BLOOD, 1999, 94 (09) :3234-3241
[8]   Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [J].
Childs, R ;
Chernoff, A ;
Contentin, N ;
Bahceci, E ;
Schrump, D ;
Leitman, S ;
Read, EJ ;
Tisdale, J ;
Dunbar, C ;
Linehan, WM ;
Young, NS ;
Barrett, AJ ;
Clave, E ;
Epperson, D ;
Mayo, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (11) :750-758
[9]   Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: Evidence for a graft-versus-tumor effect [J].
Childs, RW ;
Clave, E ;
Tisdale, J ;
Plante, M ;
Hensel, N ;
Barrett, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2044-2049
[10]   THE ROLE OF THE IMMUNE-SYSTEM IN ANTITUMOR RESPONSES - POTENTIAL FOR DRUG-THERAPY [J].
DERMIME, S ;
BARRETT, J ;
GAMBACORTIPASSERINI, C .
DRUGS & AGING, 1995, 7 (04) :266-277